From: Cardiotoxicity risk factors with immune checkpoint inhibitors
 | Persons with Cardiac Events n = 26 | Persons without Cardiac Events n = 512 | P Value |
---|---|---|---|
Demographics | |||
 Age, years [mean ± SD] | 65 ± 8 | 66 ± 11 | 0.881 |
 Gender (F) n (%1) | 16 (8.1%) | 180 (92%) | 0.011a |
 Race | |||
  Caucasian n (%1) | 19 (4%) | 449 (96%) | 0.017b |
  African American n (%1) | 7 (12%) | 50 (88%) | - |
  Other | 0 | 13 (2.5%) | - |
Cardiovascular Disease Risk Factors | |||
 BMI (kg/m2) | 25 ± 6 | 26 ± 7 | 0.308 |
 Hypertension n (%1) | 14 (4%) | 307 (96%) | 0.678 |
 Diabetes Mellitus, Type II n (%1) | 2 (7.7%) | 87 (17%) | 0.339 |
 Smoker n (%1) | 22 (6%) | 332 (94%) | 0.062 |
Immune Checkpoint Inhibitors | |||
 Pembrolizumab n (%1) | 17 (7%) | 226 (93%) | 0.055 |
 Nivolumab n (%1) | 8 (4%) | 212 (96%) | 0.383 |
 Ipilimumab n (%1) | 0 | 39 (100%) | - |
 Durvalumab n (%1) | 1 (3%) | 35 (97%) | 0.847 |
Cardiovascular Medications prior to starting ICI | |||
 Beta Blockers n (%1) | 11 (7.2%) | 141 (92.8%) | 0.103 |
 ACE/ARB n (%1) | 5 (4.1%) | 118 (95.9%) | 0.651 |
 Calcium Channel Blocker n (%1) | 6 (5.4%) | 106 (94.6%) | 0.771 |
 Diuretic n (%1) | 6 (6.9%) | 81 (93.1%) | 0.327 |
 Statin n (%1) | 10 (5.9%) | 159 (94.1%) | 0.427 |
 No Cardiovascular Medications | 6 |  |  |